RT Journal Article
T1 Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models.
A1 Peinado, Paola
A1 Andrades, Alvaro
A1 Cuadros, Marta
A1 Rodriguez, Maria Isabel
A1 Coira, Isabel F
A1 Garcia, Daniel J
A1 Álvarez-Perez, Juan Carlos
A1 Baliñas-Gavira, Carlos
A1 Arenas, Alberto M
A1 Patiño-Mercau, Juan Rodrigo
A1 Sanjuan-Hidalgo, Juan
A1 Romero, Octavio A
A1 Montuenga, Luis M
A1 Carretero, Julian
A1 Sanchez-Cespedes, Montserrat
A1 Medina, Pedro P
K1 SWI/SNF complex
K1 cell models
K1 epigenetics
K1 lung adenocarcinoma
K1 lung cancer
K1 multi-omics
AB Mammalian SWI/SNF (SWitch/Sucrose Non-Fermentable) complexes are ATP-dependent chromatin remodelers whose subunits have emerged among the most frequently mutated genes in cancer. Studying SWI/SNF function in cancer cell line models has unveiled vulnerabilities in SWI/SNF-mutant tumors that can lead to the discovery of new therapeutic drugs. However, choosing an appropriate cancer cell line model for SWI/SNF functional studies can be challenging because SWI/SNF subunits are frequently altered in cancer by various mechanisms, including genetic alterations and post-transcriptional mechanisms. In this work, we combined genomic, transcriptomic, and proteomic approaches to study the mutational status and the expression levels of the SWI/SNF subunits in a panel of 38 lung adenocarcinoma (LUAD) cell lines. We found that the SWI/SNF complex was mutated in more than 76% of our LUAD cell lines and there was a high variability in the expression of the different SWI/SNF subunits. These results underline the importance of the SWI/SNF complex as a tumor suppressor in LUAD and the difficulties in defining altered and unaltered cell models for the SWI/SNF complex. These findings will assist researchers in choosing the most suitable cellular models for their studies of SWI/SNF to bring all of its potential to the development of novel therapeutic applications.
SN 2072-6694
YR 2020
FD 2020-12-10
LK https://hdl.handle.net/10668/28417
UL https://hdl.handle.net/10668/28417
LA en
DS RISalud
RD Apr 7, 2025